Intradialytic Myocardial Stunning in Hemodialysis Patients - a Novel Cardiovascular Risk Factor
Intradialytic Myocardial Stunning in Hemodialysis Patients - a Novel Cardiovascular Risk Factor
批准号:
10544017
负责人:
David M Charytan
金额:
$69.27万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-12-24 至 2026-11-30
关键词:
AcuteAddressAmericanArrhythmiaAttentionAutonomic DysfunctionAutonomic nervous systemBaroreflexBiological MarkersBlack PopulationsBlood PressureCardiacCardiovascular systemCaringCatecholaminesCessation of lifeCitiesCollaborationsComplicationDataDedicationsDevelopmentDialysis patientsDialysis procedureEchocardiographyEnd stage renal failureEpidemiologyEventExpenditureFunctional disorderFundingHeartHeart failureHemodialysisHispanicHispanic PopulationsHormonesImpairmentIncidenceIntervention TrialInvestigationKnowledgeLeadLeftLeft Ventricular HypertrophyLifeLinkMaintenanceMeasurementMeasuresMedicareModalityMonitorMorbidity - disease rateMotionMulticenter StudiesMyocardialMyocardial IschemiaMyocardial StunningMyocardial dysfunctionNecrosisNervous System controlNeuronsNorepinephrineOsmolar ConcentrationPathogenesisPathologicPatientsPatternPhenotypePhysiologyPlasmaPopulationPositron-Emission TomographyPredispositionPrevalenceProceduresPublishingRecurrenceReflex actionResearch DesignRisk FactorsRoleSamplingStressStress cardiomyopathySubgroupSympathetic Nervous SystemSyndromeTestingTimeToxic effectUltrafiltrationUnited StatesUnited States National Institutes of HealthVariantVentricularWomanattributable mortalityautonomic reflexblack patientcardiovascular risk factorcohortdesignheart damagehemodynamicshigh riskhigh risk populationimprovedinnovationinsightmortalitymyocardial damageneuroimagingneurophysiologynew therapeutic targetnovelnovel therapeuticspatient subsetspreventresponsesudden cardiac deathtargeted treatmenttrial design
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Despite rigorous investigations and the expenditure of nearly 6% of Medicare funds on their care, annual
mortality among the 511,000 dialysis patients in the United States is extraordinarily high. Approximately, 17%
of patients die annually with half of deaths attributable to cardiovascular (CV) causes, particularly sudden
cardiac death. Current therapies do not effectively lower CV mortality in hemodialysis (HD) patients thus
highlighting the importance of addressing existing gaps in understanding of the mechanisms underlying CV
complications in HD patients and identifying novel therapeutic targets. Transient intra-dialytic myocardial
stunning (IdMS) during HD—the dominant dialysis modality in the US—has been increasingly implicated as
one such mechanism potentially responsible for progressive myocardial damage and subsequent development
of heart failure, arrhythmia, and CV death. However, current understanding of this novel risk factor is woefully
incomplete. Prior studies were small, included few women, non-white, or incident patients—those with the
highest risk of CV death—and variation in estimated prevalence was extreme (20-100%). In addition, studies of
IdMS risk factors were underpowered and conflicting, and it is remains unknown whether IdMS occurs
intermittently or repetitively. Finally, although our both our own preliminary data and studies by other groups
implicate a potential role for autonomic dysfunction in IdMS pathophysiology, there have been few mechanistic
investigations and understanding of the underlying pathophysiology is incomplete.
In short, IdMS is a potentially important and treatable contributor to CV death in the HD population, but there
are major gaps in understanding its epidemiology, risk factors, and mechanisms. We propose studies designed
to address these critical knowledge gaps and provide the necessary information to determine whether and how
IdMS should be targeted to reduce CV mortality in HD: In Aim 1, we propose performing intradialytic
echocardiography on a large, diverse cohort of 400 incident HD patients to facilitate stable, generalizable
estimates of IdMS prevalence, the analysis of important subgroups, and the study of associations with key risk
factors. In Aim 2, we propose a comprehensive investigation of the hypothesis that unopposed surges in
sympathetic tone underlie susceptibility to IdMS. Myocardial 11C-hydroxephderine PET scanning and dedicated
studies in an autonomic function lab will be utilized to assess systematic and myocardial-specific autonomic
function. Conversely, intradialytic autonomic tone and circulating hormones will be measured during dialysis to
systematically define the patterns of change in autonomic tone preceding and predisposing to episodes of
IdMS. These studies will improve understanding of the epidemiology and physiology of a potentially critical
contributor to cardiovascular morbidity and mortality in the dialysis population, improve basic understanding of
the pathophysiologic impact of HD on the heart, and provide the necessary data to design targeted
therapeutics to reduce CV death for high-risk patients.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Deep learning on ECGs to improve outcomes in patients on dialysis
-
批准号:10734856
-
项目类别:
-
资助金额:$73.54万
-
财政年份:2023
-
负责人:David M Charytan
-
依托单位:
Safety and Efficacy of Empagliflozin Main intenance HD (SEED)
-
批准号:10660436
-
项目类别:
-
资助金额:$36.46万
-
财政年份:2023
-
负责人:David M Charytan
-
依托单位:
Intradialytic Myocardial Stunning in Hemodialysis Patients - a Novel Cardiovascular Risk Factor
-
批准号:10367558
-
项目类别:
-
资助金额:$74.07万
-
财政年份:2021
-
负责人:David M Charytan
-
依托单位:
Pain, Opioids, and ESRD risk reduction with Mindfulness and Buprenorphine (POEM-B): A 3-arm multi-site randomized trial in hemodialysis patients
-
批准号:9901871
-
项目类别:
-
资助金额:$288.33万
-
财政年份:2019
-
负责人:David M Charytan
-
依托单位:
Randomized trials using point of care-guided manipulation of dialysate potassium, dialysate bicarbonate, and ultrafiltration rate to prevent hemodilaysis-associated arrythmia
-
批准号:9815883
-
项目类别:
-
资助金额:$36.72万
-
财政年份:2018
-
负责人:David M Charytan
-
依托单位:
NO, myocardial fibrosis, and microvascular rarefaction in ESRD: Pilot Studies
-
批准号:8623052
-
项目类别:
-
资助金额:$22.07万
-
财政年份:2014
-
负责人:David M Charytan
-
依托单位:
Optimizing Revascularization of Coronary Artery Disease in Chronic Kidney Disease
-
批准号:8631538
-
项目类别:
-
资助金额:$43.22万
-
财政年份:2014
-
负责人:David M Charytan
-
依托单位:
Optimizing Revascularization of Coronary Artery Disease in Chronic Kidney Disease
-
批准号:8787487
-
项目类别:
-
资助金额:$41.43万
-
财政年份:2014
-
负责人:David M Charytan
-
依托单位:
Aldosterone, nitric oxide, myocardial fibrosis, and capillary loss in ESRD
-
批准号:8506326
-
项目类别:
-
资助金额:$38.79万
-
财政年份:2013
-
负责人:David M Charytan
-
依托单位:
Aldosterone, nitric oxide, myocardial fibrosis, and capillary loss in ESRD
-
批准号:8723818
-
项目类别:
-
资助金额:$52.13万
-
财政年份:2013
-
负责人:David M Charytan
-
依托单位:
CABG and PCI for the Treatment of CAD in Individuals with CKD
-
批准号:7976398
-
项目类别:
-
资助金额:$21.94万
-
财政年份:2010
-
负责人:David M Charytan
-
依托单位:
Transforming Dialysis into a Controlled Drug Delivery System for Stem Cell Derive
-
批准号:8646760
-
项目类别:
-
资助金额:$101.69万
-
财政年份:2010
-
负责人:David M Charytan
-
依托单位:
CABG and PCI for the Treatment of CAD in Individuals with CKD
-
批准号:8117097
-
项目类别:
-
资助金额:$24.48万
-
财政年份:2010
-
负责人:David M Charytan
-
依托单位:
海外基金